天津医药
天津醫藥
천진의약
Tianjin Medical Journal
2015年
10期
1213-1216
,共4页
脊柱炎,强直性%白细胞介素23%白细胞介素17%免疫疗法%综述%IL-23/IL-17轴
脊柱炎,彊直性%白細胞介素23%白細胞介素17%免疫療法%綜述%IL-23/IL-17軸
척주염,강직성%백세포개소23%백세포개소17%면역요법%종술%IL-23/IL-17축
spondylitis,ankylosing%interleukin-23%interleukin-17%immunotherapy%review%IL-23/IL-17 axis
强直性脊柱炎（AS）发病机制至今不明，治疗效果不佳。白细胞介素（IL）-23/IL-17轴是近几年受到高度重视的重要免疫通路。本文对IL-23/IL-17轴在AS发病遗传学和免疫学中的作用进行论述，并介绍了抗IL-23和抗IL-17抗体用于治疗AS的新进展。IL-23/IL-17轴在AS发病和治疗中的重要作用提示其可能成为一个有效的新治疗靶点。
彊直性脊柱炎（AS）髮病機製至今不明，治療效果不佳。白細胞介素（IL）-23/IL-17軸是近幾年受到高度重視的重要免疫通路。本文對IL-23/IL-17軸在AS髮病遺傳學和免疫學中的作用進行論述，併介紹瞭抗IL-23和抗IL-17抗體用于治療AS的新進展。IL-23/IL-17軸在AS髮病和治療中的重要作用提示其可能成為一箇有效的新治療靶點。
강직성척주염（AS）발병궤제지금불명，치료효과불가。백세포개소（IL）-23/IL-17축시근궤년수도고도중시적중요면역통로。본문대IL-23/IL-17축재AS발병유전학화면역학중적작용진행논술，병개소료항IL-23화항IL-17항체용우치료AS적신진전。IL-23/IL-17축재AS발병화치료중적중요작용제시기가능성위일개유효적신치료파점。
The treatments for ankylosing spondylitis (AS) are still not effective, which partially due to its unclear patho?genesis. Interleukin (IL)-23/IL-17 axis is a significant immunologic pathway which has attracted much attention in the past few years. This article reviewed the role of IL-23/IL-17 axis in genetic and immunological pathogenesis of AS, and intro?duced the recent progresses in treatments of AS using anti-IL-23 or anti-IL-17 antibody. The important role of IL-23/IL-17 axis in the pathogenesis and treatment of AS indicates its potential use as a new therapeutic target.
